Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
Eun Ji Choi
Journal
- ISSN / E-ISSN
- — / —
- DOI
- 10.5045/br.2023.2023017 ↗
- Volume · Issue · Pages
- 58 · S1 · S29-S36
- Publisher
- Korean Society of Hematology
- Article URL
- https://doi.org/10.5045/br.2023.2023017 ↗
- Article details
- Unverified
Publication date (each date has its type and source)
09 Mar 2023
OpenAlex publication date · source: OpenAlex
| Type | Date | Source |
|---|---|---|
| OpenAlex publication date | 09 Mar 2023 | OpenAlex |
Keywords (as given): asciminib; allosteric kinase inhibitors; chronic myeloid leukemia; chronic phase CML; T315I mutation; tyrosine kinase inhibitor resistance; bosutinib; major molecular response; frontline treatment; tyrosine kinase inhibitors
HEC Status at Publication Not the journal's current status
HEC Status at PublicationConclusive
HEC status at publication
Recognized
Y
Based on the recorded HEC dataset applicable to the article's publication date. Listed as Y in the HEC list for 2022–23.
- Journal
- Blood Research
- Publication date used
- 09 Mar 2023 (OpenAlex publication date)
- Applicable HEC period
- 2022–23 (version 2) · 01 Jul 2022 – 30 Jun 2023
- Category
- Y
- Recognition status
- Recognized (OK_RECORD_FOUND)
- Source
- hjrs-2022-23 row 20810
- Verification status
- Verified against source · last verified 16 Oct 2026
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.